

1624

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM



(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/040,319	
	Filing Date	January 2, 2002	
	First Named Inventor	Becker, Cyrus Kephra et al.	
	Group Art Unit	1624	
	Examiner Name	Ford, John M.	
Total Number of Pages in This Submission	3	Attorney Docket Number	R0079C-REG


ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Re. Fees , pls. see under Remarks <input checked="" type="checkbox"/> Amendment / Response to Restriction Requirement <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Associate Power of Attorney <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): • Acknowledgement Postcard
RECEIVED FEB 21 2003 TECH CENTER 1600/2900		
Remarks • Applicants believe that no fees are due. However, should this not be the case, please charge any additional fees that may be required to Deposit Account No. 18-1700.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Anastasia Winslow Registration No. 40,875 Roche Palo Alto LLC, M/S A2-250 3401 Hillview Avenue, Palo Alto, CA 94304	 24372
Signature		PATENT TRADEMARK OFFICE
Date	February 13, 2003	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.:			
Typed or printed name	Iris Weise		
Signature		Date	2-13-03

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Doc. #120136v1



ATTORNEY DOCKET NO. R0079C-REG

#5
2/26/03
C. Steyer

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this paper is being deposited with the U.S. Postal Service under 37 CFR 1.8 as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington D.C. 20231, on the date indicated below.

Name of Person Mailing: Iris Weise

Signature: Iris Weise Date: 2-13-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Becker et al.

Serial No.: 10/040,319

Group Art Unit: 1624

Filed: Jan. 2, 2002

Examiner: Ford, John M.

For: QUINAZOLONE DERIVATIVES AS
ALPHA 1A/B ADRENERGIC RECEPTOR
ANTAGONISTS

RECEIVED

FEB 21 2003

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office Action mailed February 6, 2003, having a one-month shortened statutory response time due to expire on March 6, 2003, please consider the remarks below.

REMARKS

The Examiner requires restriction to one of the following inventions under 35 U.S.C.

121:

- (I) instances in claims 1-39 where Z is $-C(=O)-$; and
- (II) instances in claims 1-39 where Z is $-S(O)_2-$.

Applicant provisionally elects, with traverse, the compounds of Group I, drawn to compounds where Z is $-C(=O)-$. Applicant does not dispute the finding that the compounds

Serial No. 10/040,319

falling into Groups I and II reflect distinct inventions. However, applicant contends that a search and examination could be performed on the entire claim without serious burden and thus, restriction should not be required pursuant to MPEP §§ 803, 803.02. In particular, § 803 provides:

If the search and examination of an entire application can be made without serious burden, the examiner *must* examine it on the merits, even though it includes claims to independent or distinct inventions [MPEP §§ 803].


Likewise, § 803.02 provides:

If the members of the Markush group are sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden, the examiner must examine all members of the Markush group in the claim on the merits, even though they are directed to independent and distinct inventions [MPEP § 803.02].

Applicant submits it would not present a serious burden to examine compounds where Z is sulfonyl along with compounds where Z is carbonyl in that both have a common oxygen atom (=O) bonded at the some position of the quinazolone core. Without waiver of the foregoing, Applicant elects the Group I compounds and reserves the right to file one or more divisional applications directed to the originally presented subject matter.

Search and examination of this application is earnestly solicited. The Examiner is invited to contact the undersigned by telephone to expedite prosecution of this application.

Respectfully submitted,



Anastasia P. Winslow
Reg. No. 40,875

Roche Palo Alto LLC
Patent Law Dept. M/S A2-250
3401 Hillview Avenue
Palo Alto, CA 94304

Direct Phone: (650) 852-1141
Date: February 13, 2003